DE
SABS icon

DV Equities’s SAB Biotherapeutics SABS Stock Holding History

DV Equities’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
+400,000
New +$1.49M 0.22% 66

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DV Equities's SABS Position: Q2 2026 in Review

DV Equities opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 400,000 shares worth $1.56M. The stake represents 0.22% of the portfolio and ranks #66 among its holdings.

87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • DV Equities held 400,000 shares of SAB Biotherapeutics worth $1.56M as of Q2 2026.
  • SAB Biotherapeutics was a new DV Equities position in Q2 2026.
  • SAB Biotherapeutics made up 0.22% of DV Equities's portfolio in Q2 2026, its #66 holding.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on DV Equities's 13F filing for Q2 2026, filed 14 Aug 2026.